Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKolding Sygehus
About this trial
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.
Eligibility criteria
Qualifiers
> 18 years old
Fulfilling the 2019 EULAR/ACR classification criteria
Positive autoantibodies, medical history and obejctive examination compatible with SLE
Referred to kidney biopsy
Disqualifiers
Lack of ability or willingness to provide informed consent
Significant comorbidity, which is considered to potentially impact the outcome
> 18 years old
Fulfilling the 2019 EULAR/ACR classification criteria
Trial design
Treatments tested in this trial
- Kidney biopsy
- Urinary extracellular vesicle testing
- Autoimmunity in plasma
Treatment groups
40 Participants
are divided into 4 treatment groupsSponsors and collaborators
Kolding Sygehus
Lead sponsor
University of Southern Denmark
Collaborator
Odense University Hospital
Collaborator
Source ClinicalTrials.gov